The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models.
Romain SigaudLisa RöschCharlotte GatzweilerJulia BenzelLaura von SoostenHeike PeterzielFlorian SeltSara NajafiSimay AyhanXenia F GerloffNina HofmannIsabel BüdenbenderLukas SchmittKathrin I FoersterJuergen BurhenneWalter Emil HaefeliAndrey KorshunovFelix SahmCornelis M van TilburgDavid T W JonesStefan M PfisterDeborah KnoerzerBrent L KreiderMax SauterKristian W PajtlerMarc ZuckermannIna OehmeOlaf WittTill MildePublished in: Neuro-oncology (2022)
These data indicate a high clinical potential of ulixertinib for the treatment of pLGG and strongly support its first clinical evaluation in pLGG as single agent and in combination therapy in a currently planned international phase I/II umbrella trial.